The research behind GLP-1 care
Two of the largest weight-management trials to date were published in the New England Journal of Medicine. Here is what they found.
Semaglutide · STEP 1 trial
average body-weight reduction over 68 weeks
In the STEP 1 trial, adults taking weekly semaglutide lost 14.9% of their body weight on average, and 86% of participants lost at least 5% of their body weight.
Wilding et al., New England Journal of Medicine, 2021 ↗Tirzepatide · SURMOUNT-1 trial
body-weight reduction over 72 weeks
In SURMOUNT-1, adults taking weekly tirzepatide lost an average of 16.0% to 20.9% of their body weight depending on dose, up to 22.5%, and roughly 9 in 10 participants lost weight.
Jastreboff et al., New England Journal of Medicine, 2022 ↗Beyond the scale
Science cited growing evidence that the class blunts obesity-associated health problems, including signals for heart and metabolic health, not weight alone.
Science, Breakthrough of the Year 2023 ↗Take the free 60-second assessment. A licensed US provider reviews every request, and you only pay if you are approved.
Start my free assessment->